After 15 days, all sales are final per IVY RX's published Terms of Service
What the Evidence Shows and What It Does Not MedicalDaily Evidence Check Study type: Phase 2b randomized clinical trial Participants: 272 adults with type 2 diabetes, average age 50.8, from 37 sites in China Published in: Annals of Internal Medicine , June 30, 2026 (DOI: 10.7326/ANNALS-25-04623) What it found: Biweekly bofanglutide produced HbA1c reductions and weight loss comparable to weekly semaglutide in Chinese patients with type 2 diabetes What it did not prove: The trial was not conducted in U.S
Supporting Digestion Digestion is already a challenge for women around menopause
Crucially, the pill requires no restrictions around timing or food and water intake
It may be the difference between losing weight and losing muscle
Moreover, GIP has been found to boost glucose uptake by improving insulin sensitivity in adipocytes (176, 177), while tirzepatide has been demonstrated to enhance insulin sensitivity and promote glucose disposal in white adipose tissue in Glp-1r-null mice (178), further supporting a direct effect of GIP on adipose tissues
